- Conditions
- Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
- Interventions
- CBT, Amitriptyline
- Behavioral · Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 12 more
Clinical trials in San Francisco, California
This page shows live ClinicalTrials.gov search results for San Francisco, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in San Francisco
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Solid and Hematological Malignancies, Autoimmune Diseases
- Interventions
- Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Anitocabtagene autleucel, KITE-753, KITE-197, KITE-363, INT2104, KITE-512, SPRX001, SPRX002, ARC-T Cells
- Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2040
- U.S. locations
- 49
- States / cities
- Gilbert, Arizona • Duarte, California • La Jolla, California + 38 more
- Conditions
- Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
- Interventions
- EFG PH20 SC, PBO
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 35 more
- Conditions
- Healthy Adult Participants
- Interventions
- 0 mg oral nicotine pouches, 3 mg oral nicotine pouches, 6 mg oral nicotine pouches, cigarette or e-cigarette
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer Screening, Breast Carcinoma in Situ, Breast Cancer
- Interventions
- Complete a health questionnaire, Provide a saliva sample for genetic testing, Screening advice based on a comprehensive risk assessment, Screening advice based on a basic risk assessment
- Other · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 30 Years to 74 Years · Female only
- Enrollment
- 100,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2029
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Irvine, California • Los Angeles, California + 8 more
- Conditions
- Corneal Transplant Failure
- Interventions
- Corneal Donor Tissue with Cross Linking, Corneal Donor Tissue without Cross Linking
- Procedure
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 12
- States / cities
- Irvine, California • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- Long QT Syndrome (LQTS) 2
- Interventions
- baseline lead-in, THRV-1268
- Other · Drug
- Lead sponsor
- Thryv Therapeutics
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 6 more
- Conditions
- Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
- Interventions
- MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 4,390 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more
- Conditions
- Membranous Nephropathy, Nephrotic Syndrome
- Interventions
- Belimumab, Placebo for Belimumab, Rituximab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
- Conditions
- Hypertension in Pregnancy, Obstetrical Complications
- Interventions
- Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg, Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHg
- Drug · Other
- Lead sponsor
- The George Washington University Biostatistics Center
- Other
- Eligibility
- 14 Years to 56 Years · Female only
- Enrollment
- 4,120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more
- Conditions
- Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Emphysema
- Interventions
- LungGuard, BAROGuard
- Device
- Lead sponsor
- Paragonix Technologies
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • San Francisco, California • Stanford, California + 10 more
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Daratumumab/rHuPH20
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2040
- U.S. locations
- 837
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more